Cardiac gene editing holds promising potential in revolutionizing the landscape of cardiovascular medicine. This innovative field involves precisely modifying the genetic code within cardiac cells to address and rectify underlying genetic factors contributing to heart diseases. By leveraging advanced molecular tools such as CRISPR-Cas9, researchers aim to target specific genes associated with cardiac conditions, paving the way for personalized therapeutic interventions. The ability to edit genes directly in cardiac tissue opens new avenues for treating congenital heart disorders, genetic predispositions, and other cardiovascular ailments. While still in the early stages of development, cardiac gene editing represents a cutting-edge approach that holds great promise for advancing our understanding of cardiac health and fostering breakthroughs in tailored treatments for individuals with various cardiovascular conditions.
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation